Conmed Corp (CNMD) Reports Record Revenue Growth and Strong Earnings in Q4 and Full-Year 2023

Conmed Corp (CNMD) Announces Financial Results for Fourth Quarter and Full-Year 2023

  • Revenue: Q4 2023 net sales reached $327.0 million, a 30.4% increase from Q4 2022.
  • Full-Year Revenue: 2023 net sales totaled $1.244 billion, up 19.1% from 2022.
  • Net Income: Q4 2023 net income was $33.1 million, compared to $26.6 million in Q4 2022.
  • Full-Year Net Income: 2023 net income stood at $64.5 million, a significant improvement from a net loss in 2022.
  • Adjusted Diluted EPS: The company forecasts a 25% to 28% growth in adjusted diluted EPS for 2024.
  • 2024 Outlook: Conmed Corp expects full-year 2024 reported revenue between $1.340 billion and $1.365 billion.
Article's Main Image

On January 31, 2024, Conmed Corp (CNMD, Financial), a leading medical equipment company specializing in sports medicine and general surgery, released its 8-K filing, announcing financial results for the fourth quarter and full-year ended December 31, 2023. The company reported a robust increase in revenue and net income, signaling strong operational performance and market demand for its products.


Financial Performance Highlights

Conmed Corp's fourth quarter results showcased a significant 30.4% increase in net sales compared to the same period in the previous year, with sales reaching $327.0 million. The full-year net sales also saw a substantial rise, amounting to $1.244 billion, which is a 19.1% increase from 2022. This growth was driven by a balanced expansion across both domestic and international markets, with the Orthopedic Surgery and General Surgery segments contributing notably to the top-line improvement.

The company's net income for the fourth quarter was $33.1 million, translating to a basic EPS of $1.08 and a diluted EPS of $1.05. This performance marks a positive shift from the net loss reported in the previous year. The full-year net income also reflected a turnaround, with the company posting $64.5 million, in contrast to the net loss in 2022.

Operational and Strategic Developments

Conmed Corp's President and CEO, Curt R. Hartman, expressed pride in the company's ability to deliver record revenue, attributing the success to the strength of their product portfolio and the balanced growth across various businesses and geographies. Looking ahead to 2024, the company is optimistic about continuing to deliver innovative technology solutions to customers and patients, with an expected revenue growth of approximately 8% to 10% and a significant increase in adjusted diluted net earnings per share.

The company's financial achievements are particularly important in the competitive Medical Devices & Instruments industry, where innovation, market penetration, and operational efficiency are key drivers of success. Conmed Corp's ability to grow revenue and net income amidst these challenges is a testament to its strategic focus and execution capabilities.

Financial Metrics and Commentary

Key financial metrics from the income statement reveal a gross profit margin of 55.7% for the fourth quarter, which is an improvement from the 52.6% in the same quarter of the previous year. The full-year gross profit margin slightly decreased to 54.3% from 54.6%. Selling and administrative expenses were managed effectively, with a slight decrease in percentage of sales from the previous year.

Conmed Corp's balance sheet and cash flow statements further reflect the company's financial stability and operational efficiency. The company's management highlighted the importance of these metrics in evaluating the company's financial health and its ability to sustain growth and profitability.

"2023 was a great year for CONMED, and I am proud that our global business delivered record revenue in both the fourth quarter and for the full year," commented Curt R. Hartman, CONMED’s Chair of the Board, President, and Chief Executive Officer. "The balanced growth we saw across our various businesses and geographies is a testament to the strength of the portfolio that we have built. As we shift our focus to 2024, we are very excited to continue delivering innovative technology solutions to our customers and patients across both the General Surgery and Orthopedics categories."

The company's outlook for 2024 is positive, with an expected immaterial impact from foreign currency exchange rates. The forward-looking adjusted diluted net earnings per share for the full year 2024 are projected to grow by approximately 25% to 28%, indicating confidence in the company's future performance.


Conmed Corp's strong financial results for the fourth quarter and full year of 2023 reflect the company's successful execution of its strategic initiatives and its resilience in a dynamic market environment. The company's focus on delivering innovative solutions and driving growth across its business segments positions it well for continued success in 2024 and beyond.

For more detailed information on Conmed Corp's financial performance, readers are encouraged to review the full 8-K filing.

Explore the complete 8-K earnings release (here) from Conmed Corp for further details.